Trial · NCT00679055
A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)
NCT00679055, Phase 1, Terminated, Merck Sharp & Dohme LLC; results first posted 2015-02-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED). Trials, record NCT00679055. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00679055
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)
- NCT number
- NCT00679055
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Peripheral Vascular Diseases
- Interventions
- MK-0736, Comparator: placebo (unspecified)
- First posted
- 2008-05-16
- Last updated
- 2018-08-17
- Results first posted
- 2015-02-16
- Limitations and caveats
- Study terminated due to lack of recruitment.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Cluster of Differentiation 68 (CD68) | Baseline and Week 12 | CD68 is a heavily glycosylated transmembrane protein resident to macrophage lysosomes, and is the standard immunohistochemical (IHC) marker for macrophages in human tissues. CD68 protein content as a measure of macrophage number is the most often reported marker in clinical studies of plaque instability. Blood samples were taken to determine the level of CD69 present at baseline (predose Day 1) and again after 12 weeks of study drug administration in participants with peripheral arterial disease of the lower extremity who are scheduled for excision of an atherosclerotic plaque. |
| Secondary | Change From Baseline in Messenger Ribonucleic Acid (mRNA) | Baseline and Week 12 | mRNA is a biomarker associated with the inflammatory response. Blood samples were taken to determine the level of mRNA present at baseline (predose Day 1) and again after 12 weeks of study drug administration in participants with peripheral arterial disease of the lower extremity who are scheduled for excision of an atherosclerotic plaque. |
| Secondary | Number of Participants Who Were Discontinued From the Study Due to an Adverse Event (AE) | up to 14 weeks | An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study drug. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an AE. The percentage of participants who were discontinued from the study due to an AE was summarized. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Cluster of Differentiation 68 (CD68) | Baseline and Week 12 | Study terminated early. Planned analyses was not performed. | ||
| SECONDARY | Change From Baseline in Messenger Ribonucleic Acid (mRNA) | Baseline and Week 12 | Study terminated early. Planned analyses was not performed. | ||
| SECONDARY | Number of Participants Who Were Discontinued From the Study Due to an Adverse Event (AE) | up to 14 weeks | All enrolled participants who received at least one dose of study drug. | Particpants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Were Discontinued From the Study Due to an Adverse Event (AE) | MK-0736 | 0 | Particpants | ||
| Number of Participants Who Were Discontinued From the Study Due to an Adverse Event (AE) | Placebo | 1 | Particpants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MK-0736 | 8 | |
| Overall Study | STARTED | Placebo | 6 | |
| Overall Study | COMPLETED | MK-0736 | 6 | |
| Overall Study | COMPLETED | Placebo | 1 | |
| Overall Study | NOT COMPLETED | MK-0736 | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 5 |
Source ClinicalTrials.gov
Adverse events66
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Angina pectoris | Cardiac disorders | MK-0736 | 0 | 8 | 0 |
| other | Angina pectoris | Cardiac disorders | Placebo | 1 | 6 | 1 |
| other | Cardiac failure congestive | Cardiac disorders | MK-0736 | 0 | 8 | 0 |
| other | Cardiac failure congestive | Cardiac disorders | Placebo | 1 | 6 | 1 |
| other | Ischaemic cardiomyopathy | Cardiac disorders | MK-0736 | 0 | 8 | 0 |
| other | Ischaemic cardiomyopathy | Cardiac disorders | Placebo | 1 | 6 | 1 |
| other | Tachyarrhythmia | Cardiac disorders | MK-0736 | 0 | 8 | 0 |
| other | Tachyarrhythmia | Cardiac disorders | Placebo | 1 | 6 | 1 |
| other | Ventricular tachycardia | Cardiac disorders | MK-0736 | 0 | 8 | 0 |
| other | Ventricular tachycardia | Cardiac disorders | Placebo | 1 | 6 | 1 |
1 to 10 of 66Source ClinicalTrials.gov
See all 66 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MK-0736 | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | MK-0736 | 5 | 8 |
| Total, other adverse events | Placebo | 4 | 6 |
| Total, serious adverse events | MK-0736 | 1 | 8 |
| Total, serious adverse events | Placebo | 1 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| MK-0736 vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00679055
GET https://conductscience.org/api/trials/v1/NCT00679055/events?page=2